{"brief_title": "BMS-599626 in Patients With Advanced Solid Malignancies", "brief_summary": "The purpose of this trial is to identify the highest oral dose of BMS-599626, a drug that is directed against EGFR and HER2 proteins, that can be given safely on a daily schedule of 21 days with a 7 day rest period in patients with cancer who no longer benefit from other commonly used treatments. The study will also test for other proteins that may be affected by BMS-599626; and the level of study drug in the blood will be studied.", "condition": ["Cancer", "Metastases"], "intervention_type": ["Drug"], "intervention_name": ["panHer"], "description": ["Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached."], "arm_group_label": ["Phase 1 MTD Study"], "other_name": ["BMS-599626"], "criteria": "Inclusion Criteria: - Diagnosis of metastatic cancer that has progressed on currently available therapies; - At least 3 month life expectancy; - Primary cancer must be solid (non-hematologic); - Adequate bone marrow, liver & kidney function; - Negative pregnancy test. Exclusion Criteria: - Serious, uncontrolled medical disorder; - Individuals not willing or able to use an acceptable method to avoid pregnancy for the entire study period and for at least 3 months after the study; - Pregnant or breastfeeding women; - Patients with known brain metastasis; - Uncontrolled or significant cardiovascular disease; - Anticancer therapy within 2-6 weeks prior to study drug (depending on the therapy)", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "HER-2-expressing tumors", "id": "NCT00095537"}